Munch-a-Biotech Today Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Metcalf who wrote (1851)	5/3/2005 5:51:43 AM
From: nigel bates	Read Replies (1) of 3158

Oxford Glycoscience - Celltech beat out CAT. As for CRXA, a "single figure" royalty (funny CRXA haven't disclosed it before selling out), on a product GSK reckon has a chance of achieving $2 bn + peak sales, with a high (90% + ??) chance of approval ought to have a predictable range of values... ...and it's not as though management have made any strenuous efforts to market themselves to other parties. Self-interested wimps. (edit: "Credit Suisse First Boston recently forecast that peak sales of Cervarix could reach $4 billion a year..." siliconinvestor.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next